Board of Directors

JEFFREY BIRD, M.D., Ph.D.
Managing Director, Sutter Hill Ventures 

Dr. Jeffrey Bird is managing director, Sutter Hill Ventures, where he focuses on healthcare, including biotechnology and medical devices. In addition to Portola, he is currently a board member at AkaRx, Inc. (cancer and hematology therapeutics), Macusight (ophthalmic therapeutics), NuGen Technologies (research reagents), Restoration Robotics (aesthetic surgery devices), Roxro Pharma (pain therapeutics) and Xoft Microtube (cancer radiation devices). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics) and Barrx (gastrointestinal devices). Dr. Bird was previously senior vice president, business operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He received his B.S. from Stanford, a Ph.D. in cancer biology and an M.D. from Stanford Medical School.

Back to top

LAURA BREGE
Former President and Chief Executive Officer, Nodality, Inc.

Ms. Laura Brege is the former president and chief executive officer of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality in September 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including executive vice president and chief operating officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies, since 1999. Prior to Red Rock, she was the senior vice president and chief financial officer at COR Therapeutics. Earlier in her career, Ms. Brege served as vice president and chief financial officer at Flextronics and vice president and treasurer of The Cooper Companies. In addition to Portola, Ms. Brege currently sits on the boards of directors of the public companies Acadia Pharmaceuticals, Inc., Aratana Therapeutics, Inc., and Pacira Pharmaceuticals, Inc. Ms. Brege earned her B.A. from Ohio University (Honors Tutorial College) and an M.B.A. from the University of Chicago.

Back to top

DENNIS FENTON, Ph.D.
Owner and Chief Executive Officer, Fenton and Associates

Dr. Dennis Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm. Prior to founding Fenton and Associates, Dr. Fenton served as executive vice president of operations at Amgen, where he was responsible for worldwide operations, manufacturing, process development and quality. Dr. Fenton joined Amgen in 1982 and held numerous executive leadership roles in operations and sales and marketing. In addition to Portola, he serves on the boards of directors of Kythera Biopharmaceuticals, Inc., Hospira, Inc., Dendreon Corporation, Nora Therapeutics and XenoPort, Inc. He also serves on the board of trustees of the Keck Graduate Institute. Dr. Fenton was previously a director of the Genzyme Corporation, Genelux Corporation and Amira Pharmaceuticals. He received a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

Back to top

CHARLES HOMCY, M.D.
Former President and Chief Executive Officer, Portola Pharmaceuticals 

Dr. Charles Homcy is a venture partner at Third Rock Ventures. He co-founded Portola Pharmaceuticals in 2003 and served as president and chief executive officer from that time until April 2010. Prior to that, he was president, research and development at Millennium following Millennium’s acquisition of COR Therapeutics in 2002. Dr. Homcy joined COR in 1995 as executive vice president, research and development, and served as a director of the company from 1998 to 2002. He has been a clinical professor of medicine at the University of California, San Francisco Medical School and attending physician at the San Francisco VA Hospital since 1997. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Dr. Homcy serves on the board of directors of Geron Corporation. Dr. Homcy received his A.B. and M.D. degrees from Johns Hopkins University. 

Back to top

JOHN H. JOHNSON
Founder, Plum Brook Advisors

Mr. Johnson is a recognized leader in the pharmaceutical and biotechnology industry with more than three decades of experience. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. He recently served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). He also served as chairman, president and chief executive officer of Dendreon Corporation and as chief executive officer and a member of the board of directors of Savient Pharmaceuticals, Inc. Prior to these roles, Mr. Johnson served as president of Eli Lilly & Company’s Oncology Unit, following the company’s 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer and a member of ImClone’s Board of Directors. Prior to Imclone, Mr. Johnson served as the company group chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to that role, Mr. Johnson held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp. and Pfizer, Inc. He previously served as chairman of Tranzyme Pharma, Inc. and as a member of the board of BioNJ. Mr. Johnson is currently a member of the board of directors of Cempra Inc. and Histogenics Corporation.

Back to top

WILLIAM LIS
Chief Executive Officer, Portola Pharmaceuticals 

Mr. Lis joined Portola in 2008 and was appointed chief executive officer in May 2010. During this time, Portola has advanced several novel compounds into clinical development, successfully raised over $450 million in private and public financings, including an initial public offering in 2013, and executed multiple partnerships for its programs. Portola’s two wholly-owned thrombosis products, betrixaban and andexanet alfa, are in late-stage pivotal clinical trials, and its wholly-owned hematologic oncology agent, cerdulatinib, is advancing in a Phase 1/2a study. Prior to serving as CEO, Mr. Lis served as chief operating officer and chief business officer. He has over 20 years of biopharmaceutical experience in the areas of commercial and business development, management of drug development and executive management. Mr. Lis previously held positions at Scios, Inc. (a Johnson & Johnson Company) from 2004 to 2007 where he last served as vice president, business and commercial operations. He led successful in-licensing activities, development and commercial launch strategies and activities for Xarelto® (rivaroxaban). Prior to joining Scios, he was senior director of marketing and new products for Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.), where he directed marketing activities for Integrilin® (eptifibatide) and pipeline products. At Rhone-Poulenc Rorer, he was involved in the U.S. sales launch and commercialization of several products, including Lovenox® (enoxaparin). Mr. Lis holds a B.S. from the University of Maryland. Mr. Lis is a member of the board of directors of Biotechnology Industry Organization (BIO).

Back to top

HOLLINGS C. RENTON
Chairman of the Board 

Hollings C. Renton previously served as president and chief executive officer, director and chairman of the board of Onyx Pharmaceuticals, Inc. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton currently serves as a director at Cepheid Inc. and Kythera Biopharmaceuticals. He previously served as a director of Rigel Pharmaceuticals, Inc., Affymax Inc., Sangstat Medical Corporation, Special Olympics Northern California and the Biotechnology Industry Organization. Mr. Renton holds a B.S. in mathematics from Colorado State University and an M.B.A. from the University of Michigan.

Back to top

DAVID C. STUMP, M.D.
Former Executive Vice President, Research and Development, Human Genome Sciences, Inc. 

Dr. David Stump was most recently executive vice president, research and development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., from 1989 to 1999, most recently as vice president, clinical research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an associate professor of medicine and biochemistry at the University of Vermont. He is a member of the board of directors of Sunesis Pharmaceuticals, Inc. and MacroGenics Inc., and a member of the board of trustees of Earlham College. He earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. He is board certified in internal medicine, hematology, and medical oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis, and Vascular Biology of the American Heart Association.

Back to top

H. WARD WOLFF
Executive Vice President and Chief Financial Officer, Sangamo BioSciences, Inc. 

Ward Wolff has served as executive vice president and chief financial officer of Sangamo BioSciences since December 2007. Mr. Wolff was formerly with Nuvelo, Inc., where he served as senior vice president, finance and chief financial officer until its restructuring in August 2007. Prior to joining Nuvelo, he was chief financial officer and senior vice president, finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as senior vice president and chief financial officer of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. Mr. Wolff received a B.A. in economics from the University of California, Berkeley, and an M.B.A. from Harvard Business School.

Back to top